These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12938660)

  • 21. Clomipramine for obsessive-compulsive disorder.
    Feinberg M
    Am Fam Physician; 1991 May; 43(5):1735-8. PubMed ID: 2021107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant drugs in anxiety disorders.
    Modigh K
    Acta Psychiatr Scand Suppl; 1987; 335():57-74. PubMed ID: 3314359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of treatment-refractory obsessive compulsive disorder patients.
    Dominguez RA; Mestre SM
    J Clin Psychiatry; 1994 Oct; 55 Suppl():86-92. PubMed ID: 7961537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valproate pretreatment for the difficult-to-treat patient with OCD.
    Deltito JA
    J Clin Psychiatry; 1994 Nov; 55(11):500. PubMed ID: 7989288
    [No Abstract]   [Full Text] [Related]  

  • 25. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
    Servant D; Bailly D; Le Seac'h H; Parquet PJ
    Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial.
    Shalbafan M; Mohammadinejad P; Shariat SV; Alavi K; Zeinoddini A; Salehi M; Askari N; Akhondzadeh S
    Pharmacopsychiatry; 2015 Jul; 48(4-5):136-40. PubMed ID: 25959196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonergic probes in obsessive compulsive disorder.
    Zohar J; Kindler S
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():39-40. PubMed ID: 1517556
    [No Abstract]   [Full Text] [Related]  

  • 28. An integrated approach to treatment of obsessive compulsive disorder.
    Greist JH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():38-41. PubMed ID: 1532963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced mania.
    Mundo E; Ronchi P; Bellodi L
    Hosp Community Psychiatry; 1993 Jul; 44(7):689-90. PubMed ID: 8354514
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal.
    Gentile S
    J Clin Psychopharmacol; 2011 Oct; 31(5):625-32. PubMed ID: 21869690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
    Giger JN; Davidhizar R; Poole VL
    J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
    [No Abstract]   [Full Text] [Related]  

  • 32. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of drugs in the treatment of obsessive-compulsive disorders].
    den Boer JA; Westenberg HG
    Ned Tijdschr Geneeskd; 1990 Mar; 134(10):503-4. PubMed ID: 2107405
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():35-8. PubMed ID: 1517555
    [No Abstract]   [Full Text] [Related]  

  • 35. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II.
    Mavissakalian M; Turner SM; Michelson L; Jacob R
    Am J Psychiatry; 1985 May; 142(5):572-6. PubMed ID: 3885761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder.
    Trabert W; Hohagen F; Winkelmann G; Berger M
    Pharmacopsychiatry; 1995 May; 28(3):95-7. PubMed ID: 7568372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients.
    Jenike MA; Baer L; Summergrad P; Weilburg JB; Holland A; Seymour R
    Am J Psychiatry; 1989 Oct; 146(10):1328-30. PubMed ID: 2675643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A controlled trial of clomipramine in childhood obsessive compulsive disorder.
    Flament MF; Rapoport JL; Kilts C
    Psychopharmacol Bull; 1985; 21(1):150-2. PubMed ID: 3885292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.